{"filings":[{"id":260522,"accession_number":"0001493152-23-046217","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vicapsys Life Sciences modifies promissory note with AJB Capital, extends maturity and increases principal to $363K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity date of $330K promissory note to January 27, 2024.","Increased principal amount of note to $363,000.","Extended deadline to file registration statement for resale of conversion and commitment shares to Jan 27, 2024.","Accrued unpaid interest due on or before January 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295818,"accession_number":"0001493152-23-023183","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Vicapsys Life Sciences issues $330K note to AJB Capital, 10% interest, 8% OID, due Dec 2023","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $330,000, purchase price $303,600 (8% OID), 10% annual interest, maturity December 27, 2023.","Issued 328,571 unregistered commitment fee shares to AJB Capital as part of the agreement.","Default triggers 150% acceleration, 18% interest, and conversion at average of 3 lowest VWAP prices.","Proceeds from the note will be used for general working capital purposes.","Note is convertible into common stock upon an event of default at a formula-based conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295817,"accession_number":"0001493152-23-019905","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vicapsys Life Sciences amends patent license with Massachusetts General Hospital, adding new patent rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ninth Amendment adds Patent Rights MGH 24644 (PCT/US2018/051950) to exclusive license.","Company must submit a research and development plan for new patent rights within one year.","Company pays $2,000 non-refundable license fee and reimburses $3,956 in patent costs by July 31, 2023.","Amendment updates diligence requirements under Section 3.1 of the original 2013 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295815,"accession_number":"0001493152-23-018151","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K/A","filed_at":"2023-05-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Vicapsys Life Sciences amends 8-K to correct new auditor name to Assurance Dimensions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed D. Brooks and Associates CPAs as auditor effective May 12, 2023; their reports included a going-concern doubt.","Appointed Assurance Dimensions as new independent registered public accounting firm for fiscal year 2023 audit.","No disagreements or reportable events with former auditor during fiscal years 2021 and 2022.","This amendment solely corrects the name of the new auditor from \"Assurance.\" to \"Assurance Dimensions.\""],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295816,"accession_number":"0001493152-23-017970","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Vicapsys Life Sciences dismisses auditor D. Brooks and appoints Assurance Dimensions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board dismissed D. Brooks and Associates CPAs as independent auditor effective May 12, 2023.","Prior audit reports for FY2022 and FY2021 included a going-concern explanatory paragraph but no adverse opinions.","No disagreements or reportable events occurred during the two most recent fiscal years or interim period.","Board appointed Assurance Dimensions as new independent registered public accounting firm on May 12, 2023.","D. Brooks furnished a letter to the SEC, dated May 17, 2023, agreeing with the disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316357,"accession_number":"0001493152-23-001296","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicapsys Life Sciences enters CEO employment agreement with $250k base salary, performance-based equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Federico Pier receives $250k annual base salary, subject to annual increase by Board.","Eligible for annual cash bonus up to 100% of base salary based on performance objectives.","One-time $100k cash bonus if common stock listed on NASDAQ/NYSE or company secures $8M+ financing.","Equity awards: 1% of fully diluted shares at $250M market cap; additional 1% at $500M market cap.","Agreement has five-year term with automatic yearly renewal; severance includes 12 months base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352063,"accession_number":"0001493152-22-027017","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2022-09-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vicapsys Life Sciences: Potts and Yurkowsky resign; Farrahar, Delaney, Rosenblum join board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board accepted resignations of directors John Potts and Michael Yurkowsky effective September 22, 2022; no disagreement.","Appointed Charles 'Charlie' Farrahar (CPA, former CFO of several biotechs) as director.","Appointed Dr. Colleen Delaney, stem cell transplant physician and CSO of Deverra Therapeutics, as director.","Appointed Richard Rosenblum, President/CFO of Payment Solutions Inc. and CEO of Harborview Capital Advisors, as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369547,"accession_number":"0001493152-22-009690","cik":1468639,"company_name":"Vicapsys Life Sciences, Inc.","ticker":"VICP","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Vicapsys Life Sciences appoints Federico Pier as CEO, effective Feb 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Federico Pier appointed CEO effective Feb 15, 2022; previously interim CEO since Aug 2020 and Executive Chairman since May 2019.","Pier has 25+ years of experience in reverse mergers, structured finance, convertible debt, and equity; past roles at Oppenheimer & Co. and Bear Stearns.","Company develops VICAPSYN for transplantation and VYBRIN for post-surgical adhesions; trades OTC under symbol VICP.","The appointment was announced via press release dated April 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":47260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}